p.70 抽出テキスト

CLINICAL STATEMENTS AND GUIDELINES

June 11, 2024 Circulation. 2024;149:e1313–e1410. DOI: 10.1161/CIR.0000000000001251 e1382

51 Lin JS, Olson CM, Johnson ES, et al. The ankle-brachial index for periph-

eral artery disease screening and cardiovascular disease prediction among asymptomatic adults: a systematic evidence review for the US Preventive Services Task Force. Ann Intern Med. 2013;159:333–341. 52.	 Lindholt JS, Sogaard R. Population screening and intervention for vascular disease in Danish men (VIVA): a randomised controlled trial. Lancet. 2017;390:2256–2265. 53.	 Lindholt JS, Sogaard R, Rasmussen LM, et al. Five-year outcomes of the Danish Cardiovascular Screening (DANCAVAS) Trial. N Engl J Med. 2022;387:1385–1394. 54.	 McDermott MM, Liu K, Guralnik JM, et al. Home-based walking exercise intervention in peripheral artery disease: a randomized clinical trial. JAMA. 2013;310:57–65. 55.	 McDermott MM, Fried L, Simonsick E, et al. Asymptomatic peripheral arterial disease is independently associated with impaired lower extremity functioning: the Women's Health and Aging study. Circulation. 2000;101:1007– 1012. 56.	 McDermott MM, Applegate WB, Bonds DE, et al. Ankle brachial index values, leg symptoms, and functional performance among community-dwelling older men and women in the lifestyle interventions and independence for elders study. J Am Heart Assoc. 2013;2:e000257. 57.	 McDermott MM, Liu K, Greenland P, et al. Functional decline in peripheral arterial disease: associations with the ankle brachial index and leg symptoms. JAMA. 2004;292:453–461. 58.	 McDermott MM, Ferrucci L, Liu K, et al. Leg symptom categories and rates of mobility decline in peripheral arterial disease. J Am Geriatr Soc. 2010;58:1256–1262. 59.	 McDermott MM, Guralnik JM, Criqui MH, et al. Home-based walking exercise in peripheral artery disease: 12-month follow-up of the GOALS randomized trial. J Am Heart Assoc. 2014;3:e000711. 60.	 McDermott MM, Liu K, Ferrucci L, et al. Physical performance in peripheral arterial disease: a slower rate of decline in patients who walk more. Ann Intern Med. 2006;144:10–20. 61.	 Randhawa MS, Reed GW, Grafmiller K, et al. Prevalence of tibial artery and pedal arch patency by angiography in patients with critical limb ischemia and noncompressible ankle brachial index. Circ Cardiovasc Interv. 2017;10:e004605. 62.	 Kim ES, Sharma AM, Scissons R, et al. Interpretation of peripheral arterial and venous Doppler waveforms: a consensus statement from the Society for Vascular Medicine and Society for Vascular Ultrasound. Vasc Med. 2020;25:484–506. 63.	 Misra S, Shishehbor MH, Takahashi EA, et al. Perfusion assessment in critical limb ischemia: principles for understanding and the development of evidence and evaluation of devices: a scientific statement from the American Heart Association. Circulation. 2019;140:e657–e672. 64.	 Patry J, Laurencelle L, Belisle J, et al. Vascular assessment in patients with a lower limb wound: a correlational study of photoplethysmography and laser Doppler flowmetry toe pressure techniques. J Diabetes Sci Technol. 2020;1932296820979973. 65.	 Teso D, Sommerset J, Dally M, et al. Pedal acceleration time (PAT): a novel predictor of limb salvage. Ann Vasc Surg. 2021;75:189–193. 66.	 Sommerset J, Karmy-Jones R, Dally M, et al. Plantar acceleration time: a novel technique to evaluate arterial flow to the foot. Ann Vasc Surg. 2019;60:308–314. 67.	 Lee S, Mey L, Szymanska AF, et al. SFDI biomarkers provide a quantitative ulcer risk metric and can be used to predict diabetic foot ulcer onset. J Diabetes Complications. 2020;34:107624. 68.	 Weinkauf C, Mazhar A, Vaishnav K, et al. Near-instant noninvasive optical imaging of tissue perfusion for vascular assessment. J Vasc Surg. 2019;69:555–562. 69.	 Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA/ACC guide-

line on the management of patients with lower extremity peripheral artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017;135:e726–e779.

3.2 Imaging for PAD 1.	 Burbelko M, Augsten M, Kalinowski MO, et al. Comparison of contrast-en-

hanced multi-station MR angiography and digital subtraction angiography of the lower extremity arterial disease. J Magn Reson Imaging. 2013;37:1427– 1435. 2.	 Met R, Bipat S, Legemate DA, et al. Diagnostic performance of computed

tomography angiography in peripheral arterial disease: a systematic review and meta-analysis. JAMA. 2009;301:415–424. 3 Menke J, Larsen J. Meta-analysis: accuracy of contrast-enhanced magnetic

resonance angiography for assessing steno-occlusions in peripheral arterial disease. Ann Intern Med. 2010;153:325–334. 4.	 de Vries SO, Hunink MG, Polak JF. Summary receiver operating characteristic curves as a technique for meta-analysis of the diagnostic performance of duplex ultrasonography in peripheral arterial disease. Acad Radiol. 1996;3:361–369. 5.	 Mestre XM, Castellote MA, Coll RV, et al. Arterial mapping with Duplex ultrasound: diagnostic-therapeutic strategy in patients with critical lower-limb ischemia. Int Angiol. 2009;28:209–214. 6.	 Martinelli O, Alunno A, Drudi FM, et al. Duplex ultrasound versus CT angiography for the treatment planning of lower-limb arterial disease. J Ultrasound. 2021;24:471–479. 7.	 Andreucci M, Solomon R, Tasanarong A. Side effects of radiographic contrast media: pathogenesis, risk factors, and prevention. Biomed Res Int. 2014;2014:741018. 8.	 Stacul F, van der Molen AJ, Reimer P, et al. Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines. Eur Radiol. 2011;21:2527–2541. 9.	 McCullough PA, Capasso P. Patient discomfort associated with the use of intra-arterial iodinated contrast media: a meta-analysis of comparative randomized controlled trials. BMC Med Imaging. 2011;11:12. 10.	 Woolen SA, Shankar PR, Gagnier JJ, et al. Risk of nephrogenic systemic fibrosis in patients with stage 4 or 5 chronic kidney disease receiving a group II gadolinium-based contrast agent: a systematic review and meta-analysis. JAMA Intern Med. 2020;180:223–230. 11.	 Zhang B, Liang L, Chen W, et al. An updated study to determine association between gadolinium-based contrast agents and nephrogenic systemic fibrosis. PLoS One. 2015;10:e0129720. 12.	 American College of Radiology. ACR Manual on Contrast Media. 2022. Accessed January 5, 2023. https://www.acr.org/-/media/acr/files/clinicalresources/contrast_media.pdf. 13.	 Cavallo AU, Koktzoglou I, Edelman RR, et al. Noncontrast Magnetic Reso-

nance Angiography for the Diagnosis of Peripheral Vascular Disease. Circ Cardiovasc Imaging. 2019;12:e008844. 4.1. Amplifiers of Cardiovascular and Limb-Related Risks in Patients with PAD 1.	 Elhadd T, Robb R, Jung R, et al. Pilot study of prevalence of asymptomatic peripheral arterial occlusive disease in patients with diabetes attending a hospital clinic. Practical Diabetes Int. 1999;16:163–166. 2.	 Lange S, Diehm C, Darius H, et al. High prevalence of peripheral arterial disease but low antiplatelet treatment rates in elderly primary care patients with diabetes. Diabetes Care. 2003;26:3357–3358. 3.	 Escobar C, Blanes I, Ruiz A, et al. Prevalence and clinical profile and management of peripheral arterial disease in elderly patients with diabetes. Eur J Intern Med. 2011;22:275–281. 4.	 Mohammedi K, Woodward M, Hirakawa Y, et al. Presentations of major peripheral arterial disease and risk of major outcomes in patients with type 2 diabetes: results from the ADVANCE-ON study. Cardiovasc Diabetol. 2016;15:129. 5.	 Shammas AN, Jeon-Slaughter H, Tsai S, et al. Major limb outcomes following lower extremity endovascular revascularization in patients with and without diabetes mellitus. J Endovasc Ther. 2017;24:376–382. 6.	 Sen P, Demirdal T, Emir B. Meta-analysis of risk factors for amputation in diabetic foot infections. Diabetes Metab Res Rev. 2019;35:e3165. 7.	 Duval S, Long KH, Roy SS, et al. The contribution of tobacco use to high health care utilization and medical costs in peripheral artery disease: a state-based cohort analysis. J Am Coll Cardiol. 2015;66:1566–1574. 8.	 Hirsch AT, Treat-Jacobson D, Lando HA, et al. The role of tobacco cessation, antiplatelet and lipid-lowering therapies in the treatment of peripheral arterial disease. Vasc Med. 1997;2:243–251. 9.	 Brar A, Stefanov DG, Jindal RM, et al. Mortality on the kidney waiting list and after transplantation in patients with peripheral arterial disease: an analysis of the United States Renal Data System. Transplant Proc. 2016;48:15–20. 10.	 O'Hare AM, Glidden DV, Fox CS, et al. High prevalence of peripheral arterial disease in persons with renal insufficiency: results from the National Health and Nutrition Examination Survey 1999-2000. Circulation. 2004;109:320– 323. 11.	 Lash JP, Go AS, Appel LJ, et al. Chronic Renal Insufficiency Cohort (CRIC) Study: baseline characteristics and associations with kidney function. Clin J Am Soc Nephrol. 2009;4:1302–1311. 12.	 Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial

disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation. 2004;110:738–743.

Downloaded from http://ahajournals.org by on October 7, 2026